BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20048171)

  • 1. Functional p53 status as a biomarker for chemotherapy response in oral-cavity cancer.
    Mroz EA; Rocco JW
    J Clin Oncol; 2010 Feb; 28(5):715-7. PubMed ID: 20048171
    [No Abstract]   [Full Text] [Related]  

  • 2. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
    Perrone F; Bossi P; Cortelazzi B; Locati L; Quattrone P; Pierotti MA; Pilotti S; Licitra L
    J Clin Oncol; 2010 Feb; 28(5):761-6. PubMed ID: 20048189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [p53 mutations and chemoresistance in oromaxillofacial squamous-cell carcinomas. The results of a molecular genetics study of p53 in metastatic oromaxillofacial tumors and an evaluation of the response to neoadjuvant chemotherapeutic treatment].
    Cutilli T; Papola F; Di Emidio P; Leocata P; Corbacelli A
    Minerva Stomatol; 1998; 47(1-2):1-9. PubMed ID: 9578641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neoadjuvant radiochemotherapy for squamous cell carcinoma of the oral cavity].
    Bootz F
    HNO; 2008 Feb; 56(2):183-4. PubMed ID: 18231725
    [No Abstract]   [Full Text] [Related]  

  • 5. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
    Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J
    J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
    Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
    Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organ preservation: III.
    Hanna EY
    Curr Oncol Rep; 2001 Jan; 3(1):45. PubMed ID: 15849886
    [No Abstract]   [Full Text] [Related]  

  • 8. Retrospective analysis on prognostic impact of adjuvant chemotherapy in the patients with advanced and resectable oral squamous cell carcinoma.
    Kurita H; Koike T; Miyazawa H; Uehara S; Kobayashi H; Kurashina K
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):915-21. PubMed ID: 16835480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival in locally advanced oral cavity cancer: an analysis of patients treated with neoadjuvant cisplatin-based chemotherapy followed by surgery.
    Ruggeri EM; Carlini P; Pollera CF; De Marco S; Ruscito P; Pinnarò P; Nardi M; Giannarelli D; Cognetti F
    Head Neck; 2005 Jun; 27(6):452-8. PubMed ID: 15880411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma.
    Nakashima S; Natsugoe S; Matsumoto M; Kijima F; Takebayashi Y; Okumura H; Shimada M; Nakano S; Kusano C; Baba M; Takao S; Aikou T
    Anticancer Res; 2000; 20(3B):1933-7. PubMed ID: 10928129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of a surgical method in combined and complex treatment of patients with squamous cell oral and oropharyngeal cancer].
    Vikhlianov IV; Shoĭket IaN; Lazarev AF
    Khirurgiia (Mosk); 2007; (1):55-8. PubMed ID: 17426691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
    Licitra L; Suardi S; Bossi P; Locati LD; Mariani L; Quattrone P; Lo Vullo S; Oggionni M; Olmi P; Cantù G; Pierotti MA; Pilotti S
    J Clin Oncol; 2004 Dec; 22(24):4901-6. PubMed ID: 15611505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive assay of neoadjuvant chemotherapy in management of oral cancer.
    Tsuji T; Noguchi M; Kido Y; Kubota H; Takemura K; Nakamori K; Hiratsuka H
    Int J Oral Maxillofac Surg; 2007 Jan; 36(1):15-9. PubMed ID: 17157477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
    Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
    Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of p53 protein as a prognostic factor for oral cancer surgery.
    Cutilli T; Leocata P; Dolo V; Altobelli E
    Br J Oral Maxillofac Surg; 2013 Dec; 51(8):922-7. PubMed ID: 23791033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma.
    Nakazawa M; Ohnishi T; Ohmae M; Chisoku H; Yui S; Iwai S; Sumi T; Fukuda Y; Kishino M; Yura Y
    Int J Clin Pharmacol Res; 2005; 25(3):115-22. PubMed ID: 16366419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy in early-stage and locally advanced small bulk squamous cell carcinoma of the oral cavity and oropharynx.
    Tichler T; Ramon Y; Rath P; Hendler S; Brenner HJ
    Isr J Med Sci; 1988; 24(9-10):539-44. PubMed ID: 2462551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of quality of life of patients with oral squamous cell carcinoma. Comparison of two treatment protocols in a prospective study-first results].
    Wiltfang J; Grabenbauer G; Bloch-Birkholz A; Leher A; Neukam FW; Kessler P
    Strahlenther Onkol; 2003 Oct; 179(10):682-9. PubMed ID: 14566476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical studies of preoperative tumor reductive chemotherapy with PPV regimen in the treatment of oral squamous cell carcinoma].
    Jin Y; Shen Y; Ma G
    Zhonghua Kou Qiang Yi Xue Za Zhi; 1995 May; 30(3):166-8. PubMed ID: 7489653
    [No Abstract]   [Full Text] [Related]  

  • 20. [p53 mutation and chemoresistance in oral-maxillofacial squamous cell carcinoma. Role of p53 in the cell cycle control and in the modulating action of chemotherapeutic agents].
    Cutilli T; Papola F; Di Emidio P; Corbacelli A
    Minerva Stomatol; 1997 Dec; 46(12):671-8. PubMed ID: 9567617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.